Opioid-Induced Pruritus Management

Mechanism and Epidemiology

The pathophysiology of opioid-induced pruritus involves direct activation of central mu-opioid receptors in the CNS, and the mu-opioid receptor system plays a central role in this condition, as evidenced by the efficacy of mu-opioid receptor antagonists in treating it, affecting 10-50% of patients receiving intravenous opioids 1, 2
Opioid-induced pruritus is extremely common and varies by route of administration, with 2-10% of patients experiencing it with oral opioids, 10-50% with intravenous opioids, and 20-100% with epidural/intrathecal opioids 1, 2, 3, 4

The British Association of Dermatologists recommends antihistamines as the initial treatment for opioid-induced pruritus, despite limited mechanistic rationale, with diphenhydramine 25-50 mg orally as first-line therapy 3, 5
If antihistamines are ineffective, mu-opioid receptor antagonists such as naloxone or naltrexone can be used with careful dose titration to avoid reversing analgesia, and methylnaltrexone may preserve analgesia better 1, 3, 6
Mixed agonist-antagonists like nalbuphine can treat pruritus while maintaining some analgesia 1

Mirtazapine 30 mg daily has been shown to prevent morphine-induced pruritus in surgical settings, and gabapentin 1200 mg daily in divided doses is another preventive option 1, 5

The British Association of Dermatologists guidelines explicitly state that ondansetron and other 5-HT3 antagonists do not reduce the incidence or time to onset of opioid-induced pruritus compared to placebo, and should not be used for this condition 1, 4, 3, 5
Full doses of opioid antagonists should not be administered without careful titration, as this risks reversing analgesia and inducing significant pain 1, 3, 6